{"content":[{"text":"“It’s incredibly challenging to develop drugs for acute myeloid leukaemia as the \n disease is often aggressive and prone to resistance, so survival rates are currently \n poor for many patients. I’m excited by the potential of EP0042 and, as new \n treatments are urgently needed for people with this diagnosis, I really hope to see a \n positive impact on patient outcomes following this phase I trial.","bbox":{"left":0.120984,"top":0.083595,"width":0.743042,"height":0.09500599999999998}},{"text":"“EP0042 is a great example of the highly collaborative ‘bench-to-bedside’ approach \n of The Royal Marsden and ICR, with researchers working closely with clinicians to \n pioneer new and increasingly personalised treatments in order to improve and save \n the lives of cancer patients throughout the UK and beyond. We are also hugely \n encouraged by the involvement and support of Ellipses in the development of this \n drug.”","bbox":{"left":0.120984,"top":0.189804,"width":0.743032,"height":0.11379700000000001}},{"text":"Dr Olivia Rossanese, Head of Cancer Therapeutics at the ICR, said:","bbox":{"left":0.120984,"top":0.314769,"width":0.643073,"height":0.019627000000000006}},{"text":"“EP0042 is an innovative drug, targeting both Aurora and Flt3, and could ultimately \n counteract drug resistance in cancers including acute myeloid leukaemia and \n neuroblastoma.","bbox":{"left":0.120984,"top":0.345484,"width":0.737029,"height":0.057211999999999985}},{"text":"“It’s always a real pleasure to see one of our drugs enter phase I trials – it’s the \n culmination of our work to translate our scientific understanding of how cancer grows \n into new therapies to treat patients. And it’s a reminder of the power of effective \n collaborations, with industry and our partners at The Royal Marsden, to develop and \n deliver new medicines to patients.”","bbox":{"left":0.120984,"top":0.413899,"width":0.753578,"height":0.09498300000000004}},{"text":"Dr Rajan Jethwa, Chief Executive Officer of Ellipses Pharma, said:","bbox":{"left":0.120984,"top":0.520038,"width":0.632776,"height":0.01962699999999995}},{"text":"“The creation and commencement of this trial reflects our commitment to \n accelerating the development of promising and innovative cancer treatments. We are \n delighted to be working collaboratively with the ICR and the Royal Marsden to take \n this exciting trial forward.”","bbox":{"left":0.120984,"top":0.553172,"width":0.757364,"height":0.07250800000000002}},{"text":"Professor Paul Workman, Chief Executive at the ICR, said:","bbox":{"left":0.120984,"top":0.638053,"width":0.558879,"height":0.01962699999999995}},{"text":"“This new drug is an excellent example of how the ICR is working to discover new \n treatments that overcome the ability of cancers to adapt, evolve and become \n resistant to treatment.","bbox":{"left":0.120984,"top":0.668769,"width":0.7284790000000001,"height":0.05721200000000015}},{"text":"“Cancer evolution by Darwinian natural selection is the greatest challenge we face in \n the treatment of cancer – indeed, it is one of the greatest challenges in modern \n medicine – and will be the focus of our research at our new Centre for Cancer Drug \n Discovery, which will further enhance our work to create a new generation of \n resistance-busting treatments to benefit cancer patients.”","bbox":{"left":0.120984,"top":0.73722,"width":0.75261,"height":0.09498300000000004}},{"text":"Discovery and development","bbox":{"left":0.120984,"top":0.843334,"width":0.267587,"height":0.01962699999999995}},{"text":"The discovery and initial development of EP0042 was carried out by scientists in the \n ICR’s Cancer Research UK Cancer Therapeutics Unit, largely funded by Cancer","bbox":{"left":0.120984,"top":0.874045,"width":0.7496940000000001,"height":0.03839800000000004}}],"images_bbox":[],"images_bbox_not_text_overlap":[]}